Skip to content

Donation Advisor Clinical Decision Support Tool Study

Implementation of Donation Advisor, a Personalized Clinical Decision Support Tool for Improved Efficiency and Effectiveness of Deceased Organ Donation and Transplantation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04661787
Enrollment
36
Registered
2020-12-10
Start date
2021-01-11
Completion date
2023-12-19
Last updated
2026-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Organ Donation

Keywords

Organ Donation after Circulatory Determined Death (DCD), Clinical Decision Support Tool, Organ Donation, Organ Transplantation, DCD

Brief summary

Every year, thousands of Canadians receive life-saving, cost-effective organ transplants, while thousands more still wait or die because not enough organs are available. Patients with non-recoverable illnesses, who are undergoing withdrawal of life sustaining measures, can donate their organs when they die by a process called donation after circulatory determined death (DCD). However, over 30% of all DCD attempts are unsuccessful because patients do not die within the time frame required for healthy organ retrieval and prolonged exposure to low oxygen during the dying process renders organs unsuitable for transplantation. Predicting successful DCD is difficult and leads to uncertainty in the clinical community. To address this issue, the investigators have developed a clinical decision support tool called Donation Advisor (DA) that will assist the healthcare team in identifying successful DCD donors and will provide an improved assessment of the health of their organs. The investigators are ready to implement DA and evaluate its impact in 7 hospitals in Ontario. The investigators believe use of DA will reduce unsuccessful DCD attempts, enhance family experience of donation, optimize system costs, and improve transplant outcomes

Interventions

None listed

Sponsors

Canadian Blood Services
CollaboratorOTHER
Health Canada
CollaboratorOTHER_GOV
Canadian National Transplant Research Program
CollaboratorOTHER
The Physicians' Services Incorporated Foundation
CollaboratorOTHER
The Ottawa Hospital
CollaboratorOTHER
Unity Health Toronto
CollaboratorOTHER
Kingston Health Sciences Centre
CollaboratorOTHER
London Health Sciences Centre
CollaboratorOTHER
Sunnybrook Health Sciences Centre
CollaboratorOTHER
Hamilton Health Sciences Corporation
CollaboratorOTHER
University Health Network, Toronto
CollaboratorOTHER
Ottawa Hospital Research Institute
Lead SponsorOTHER
Gift of Life
CollaboratorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* for Organ Donation Patients: All patients eligible for DCD and whose substitute decision makers (SDMs) have been approached for consent by a Trillium Organ Tissue Donation Coordinator (OTDC). * for Organ Transplant Recipient Patients - All patients at any of the Transplant Centres participating in this study who are transplant recipients of the organs from enrolled donor patients. * for Health Care Professionals for Interviews to provide feedback on the Donation Advisor Tool - All physicians (donation and transplantation), bedside nurses and OTDCs who either have the potential to be involved in the care of study patients, or who been directly involved in the care of the study patients.

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Waveform collection from the bedside monitorFrom date and time of enrollment until the date and time of declaration of death, assessed up to 6 hours post withdrawal of life sustaining measuresHeart rate, systolic, mean and diastolic blood pressure and oxymetry will be downloaded from the bedside monitor. Automated algorithms will assess the quality of the waveform data, and detect the necessary fiducial markers (R peaks, systolic and diastolic peaks, and pulse pressure measurements), and perform cleaning of artifacts, missing data and noise, to form vital signs time series, which will be used to calculate variability metrics for the patient.
Systemic IschemiaFrom the date and time of withdrawal of life sustaining measures until the date and time of declaration of death, assessed up to 6 hoursDuration of time when the systolic blood pressure and/or oxygen saturation fall below physiologic thresholds indicating organ ischemia
Efficacy of DCD outcome prediction by the Donation Advisor (DA) ToolFrom the date and time of withdrawal of life sustaining measures until the date and time of declaration of death, assessed up to 6 hoursThe predictive capacity of the models to accurately identify time between withdrawal of Life Sustaining Measures (WLSM) and death will be documented.
Donation Advisor (DA) Tool ReportFrom the date and time the Research Coordinator initiates the report to the date and time the report displays, assessed up to 1 weekTime to create the DA Report
Enduser feedback on the Donation Advisor Tool Usability and FeasibilityUp to 1 week post declaration of death following withdrawal of life sustaining measuresData with be collected using 'Thinking aloud interviews' where Health Care Professional with review DA Reports. Data captured: misunderstandings, pauses, repetitions, and expressions of frustration or confusion. These "usability problems" will become target areas for improvements on subsequent versions of the tool. A series of direct questions will allow the interviewee to report on overall usability (clarity, ease of navigation) and usefulness of the tool. They will be asked about the feasibility and usefulness of using a tool like this in their clinical practice, as well as the amount of time one could reasonably expect a physician to spend with a tool like this in their clinical practice, to inform the final design goals for the tool. Finally, interviewees will be asked to report as many potential barriers to and drivers of use of the tool as they can.
Success of Organ Transplantationsat 28 days from organ transplantation or hospital discharge if sooner than 28 daysIncluding attempted DCD with no organs retrieved, The undergoing of DCD with at least one organ transplanted Number of organs donated per donor Failed organ transplants (i.e. proportion of organs discarded due to excessive warm ischemia time, or that fail after transplant) Proportion of recipients with early transplant graft dysfunction.

Secondary

MeasureTime frameDescription
Resources and associated costs to further develop and expand implementation of the DA toolthrough study completion, an average of 2 yearsEstimate of required resources and associated costs to further develop and expand implementation of the DA tool - The investigators will assess the economic feasibility of DA tool by calculating the cost of developing and implementing DA tool. A blended micro- and gross- costing approach will be used. The investigators will develop a data collection form to collect resource use for developing, operating, and maintaining the DA tool. Their unit costs will be obtained from program financial records, service level agreements, and the program budget with a close consultation with the project staff

Countries

Canada

Contacts

PRINCIPAL_INVESTIGATORSonny Dhanani, MD

CHEO-RI

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 5, 2026